查詢結果分析
相關文獻
- Ganglioglioma in Children--A Case Report
- 2-Aminofluorene-DNA Adducts formation in Rat Glial Cultured Tumor Cells
- Prognostic Factors and Results of Radiotherapy for Brain Stem Gliomas
- Functional Brain Mapping-Assisted Resection of Gliomas in the Dominant Hemisphere
- 腦部原發性神經膠質瘤(Gliomas)之病理學診斷
- Proton Magnetic Resonance Spectroscopy of Cerebral Glioma after Irradiation
- Intracranial Ganglioglioma: CT and MRI Findings
- Dibutyryl cAMP Down-Regulates Gene Expression of Endothelin Receptor a Subtype in Rat Astrocytoma C6 Cells
- Effects of Insulin on Protein Phosphorylation and Protein Kinase C Activity in Human Malignant Gliomas
- MR Findings of Brainstem Ganglioglioma: Case Report and Review of the Literature
頁籤選單縮合
題 名 | Serum Concentration of Soluble Decoy Receptor 3 in Glioma Patients before and after Surgery=腦神經膠質瘤患者手術前後DcR3血清濃度的變化 |
---|---|
作 者 | 黃旭霖; 林志隆; 鄭琪云; 林映凡; 劉安祥; 洪純隆; 李昆興; | 書刊名 | The Kaohsiung Journal of Medical Sciences |
卷 期 | 20:3 2004.03[民93.03] |
頁 次 | 頁124-127 |
分類號 | 416.291 |
關鍵詞 | 神經膠質瘤; Decoy receptor 3; Glioma; |
語 文 | 英文(English) |
中文摘要 | 免疫反應抑制作用於惡性腦神經膠質瘤中被証實,與腫瘤的發生也有相關。最近發現的decoy receptor 3 (DcR3)可以結合CD95L和LIGHT,抑制兩者的程式性自殺(apoptosis)的作用。目前只有少數文獻報導惡性腦神經膠質瘤分泌DcR3。本研究以17位惡性腦神經膠質瘤為對象,抽血檢查DcR3的血清濃度。手術前的DcR3的濃度0.069±0.027 ng/mL,手術後為0.068±0.022ng/mL,兩者並無統計學的意義(p=0.951)。與控制組的DcR3濃度(0.063±0.023ng/mL)比較,惡性腦神經膠質患者的DcR3濃度也無統計學上的差異(p=0.106)。我們的研究顯示,惡性腦神經膠質瘤手術前後的DcR3血清濃度並無明顯差異,惡性腦神經膠質瘤患者與控制組DcR3血清濃度也並無差異,結果顯示DcR3雖是一種可溶解接受器(soluble receptor),其作用可能侷限於分泌細胞附近。因此,腫瘤細胞DcR3的表現與血清DcR3濃度的關係需進一步研究釐清。 |
英文摘要 | The suppression of immune responses in malignant gliomas is thought to be involved in glioma pathogenesis. The newly identified tumor-secreted soluble decoy receptor 3 (DcR3) can bind to the ligands CD95L and LIGHT, thereby neutralizing their pro-apoptotic actions. Little is known of the production of DcR3by glioma cells. This study investigated the serum concentration of DcR3 in glioma patients before and after tumor removal. Blood samples were taken from 17 glioma patients and 10 control patients. The serum DcR3 concentration was measured using a DcR3 enzyme-linked immunosorbent assay. There was no statistically significant difference between preoperative (0.069±0.027 ng/mL) and postoperative DcR3 concentrations (0.068±0.022 ng/mL; p=0.951). Similarly, there was no difference in preoperative DcR3 concentration between glioma patients (0.069±0.027 ng/mL) and controls (0.063±0.023 ng/mL; p=0.106). Our study demonstrated no alteration in DcR3 concentration in glioma patients before and after tumor removal. |
本系統中英文摘要資訊取自各篇刊載內容。